Zenas BioPharma, Inc. financial data

Symbol
ZBIO on Nasdaq
Location
852 Winter Street, Suite 250, Waltham, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 589 %
Debt-to-equity 27.7 %
Return On Equity -73.6 % -158%
Return On Assets -57.6 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 53.7M shares +28.4%
Common Stock, Shares, Outstanding 42.2M shares +1.04%
Entity Public Float 0 USD
Common Stock, Value, Issued 4K USD 0%
Weighted Average Number of Shares Outstanding, Basic 42.2M shares +448%
Weighted Average Number of Shares Outstanding, Diluted 42.2M shares +448%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Revenue from Contract with Customer, Excluding Assessed Tax 10M USD
Research and Development Expense 162M USD +2.6%
General and Administrative Expense 49.2M USD +76.8%
Operating Income (Loss) -201M USD -28.3%
Nonoperating Income (Expense) 11M USD -54.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -190M USD -33.4%
Income Tax Expense (Benefit) 20K USD
Net Income (Loss) Attributable to Parent -190M USD -47.2%
Earnings Per Share, Basic 31 USD/shares +75.7%
Earnings Per Share, Diluted 31 USD/shares +75.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 116M USD -67.9%
Cash, Cash Equivalents, and Short-term Investments 302M USD -22%
Assets, Current 297M USD -24.7%
Property, Plant and Equipment, Net 50K USD -65.8%
Operating Lease, Right-of-Use Asset 807K USD +102%
Other Assets, Noncurrent 13.8M USD +53%
Assets 322M USD -20.2%
Accounts Payable, Current 6.44M USD -57.3%
Employee-related Liabilities, Current 8.76M USD +41.5%
Accrued Liabilities, Current 45.4M USD +59%
Liabilities, Current 52.4M USD +19.1%
Operating Lease, Liability, Noncurrent 180K USD
Liabilities 126M USD +185%
Accumulated Other Comprehensive Income (Loss), Net of Tax -69K USD -228%
Retained Earnings (Accumulated Deficit) -525M USD -56.7%
Stockholders' Equity Attributable to Parent 196M USD -45.4%
Liabilities and Equity 322M USD -20.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -37.1M USD -94%
Net Cash Provided by (Used in) Financing Activities 99K USD
Net Cash Provided by (Used in) Investing Activities -86.3M USD -392055%
Common Stock, Shares Authorized 175M shares 0%
Common Stock, Shares, Issued 42.2M shares +1.04%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -123M USD -526%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 116M USD -67.9%
Deferred Tax Assets, Valuation Allowance 90.3M USD +127%
Deferred Tax Assets, Gross 90.9M USD +127%
Operating Lease, Liability 798K USD -99.8%
Depreciation 23K USD -30.3%
Payments to Acquire Property, Plant, and Equipment 18K USD -18.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -190M USD -33.2%
Lessee, Operating Lease, Liability, to be Paid 834K USD
Operating Lease, Liability, Current 618K USD +60.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 138K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 457K USD +4.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure -38.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 36K USD
Deferred Tax Assets, Operating Loss Carryforwards 29.6M USD +197%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 25M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 721M USD +3.89%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 24.3M USD +158%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%